Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials

Cancer Treatment Reviews · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles